TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: 2-hour pain-relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SPF rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of CA 15‐3 for bone metastases diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: successful bowel preparation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: willingness to repeat the same protocol
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: rate of nausea/vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: percent-correct score in the Diagnosis Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-h AUC glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 1-h postprandial glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 2-h postprandial glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ease of use perception
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: improvement in psychotic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of CRC screening within guidelines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vasoconstriction response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Time to regression of sensory analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Repeatability for intolerance status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Repeatability of AUCs of GI symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Repeatability for malabsorber status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: EQ-VAS score improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Antiemetic effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annualized height velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in height Z score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum CC16 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean decrease in foveal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best-corrected log-MAR visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pregnancy rates (PRs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: patient discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: candidate skill level
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Western Ontario and McMaster Universities Osteoarthritis Index response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: report of minor adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Composite of myocardial infarction or stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean wrist function (DASH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean cortisol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: duration of the quiescent period of the cortisol rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: sleep improvement
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: take-home baby rate
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: embryo grading
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Operating Room (OR) time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average lesion size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of SSIs within 30 days of surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Time required to induce the development of healthy granulation tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total duration of hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: mean number of persisting pockets >4 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bleeding on probing that required further treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical benefit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in iPTH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in proximal femur BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Reduction in BPRS or CGI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of administration
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: TNFR-2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Success rate of pulp treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Oxford Knee Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: increase in oxidized albumin levels (f(HNA‐1) and f(HNA‐2))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in plasma protein carbonyl content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gestational diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Large for gestational age (LFGA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Lack of MEPs in lower limb muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Response maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maintaining independence in older adults
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in UAER
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Days from surgery to a dry incision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative deep infections
Endpoint domain: Adverse events/effects
Primary endpoint: Patient charge
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Tolerability of nabumetone and meloxicam
Endpoint domain: Adverse events/effects
Primary endpoint: Patient satisfaction with misoprostol administration
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Staff recommendation of sublingual administration
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of adverse effects (nausea, vomiting, diarrhea, unpleasant mouth taste)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean absolute error in size estimation of breast masses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: New York Heart Association (NYHA) functional class
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of blood doping detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Case-finding yield
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost-per case detected
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: sIgA secretion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean area under the glycaemic response curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUC of insulin in response to wheat-containing meals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ad libitum food intake over the next 10 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fat-free mass (FFM) changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PHQ-9 scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of transfusions required
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Ventilation-free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Achieved control of LDL-C after 36 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pgp activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duodenal MDR1 mRNA expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pgp detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to load and prime inhaler device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection rate of PFO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain transit time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative urinary tract infection incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean change from baseline to week 48 in DAS28‐C‐reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACR20, ACR50, and ACR70 response rates at week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health Assessment Questionnaire Disability Index improvements
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: endosinus bone gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peri-implant bone level change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serious adverse events related to implant surgery
Endpoint domain: Adverse events/effects
Primary endpoint: SF36 vitality scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reduction of central and peripheral blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pulse pressure amplification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: serum CK activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bond failure rate
Endpoint domain: Adverse events/effects
Primary endpoint: Serum level of sCD44v6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of recurrent VTE
Endpoint domain: Mortality/survival
Primary endpoint: E2 plasma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dissolution of softgel capsule
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaginal discharge
Endpoint domain: Adverse events/effects
Primary endpoint: incidence rate of malaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Decisional conflict levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Odds of making a decision about prophylactic treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Survival rates at 1 and 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Visual analog scale score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oswestry disability index decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: three-year recurrence risk
Endpoint domain: Mortality/survival
Primary endpoint: Submucosa thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression levels of TGF‐β(1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression levels of CD34
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction rates of nursing work
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Average hospital stays
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Mastery rates of health knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Rhinomanometric assessment improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Saccharin transit time decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean cumulative morphine and tramadol consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Quality of analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HRC index prior to diagnosis of UTI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HRC index prior to diagnosis of BSI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-efficacy for breathing technique
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinical benefit (partial response and stable disease)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: small artery compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Regression of coronary atherosclerotic plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Dyspnea score (Borg scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Average absolute difference between MVPA%true and MVPA%SOFIT estimates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intubation success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PaO₂ levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Progression or death
Endpoint domain: Mortality/survival
Primary endpoint: Sensitivity of TEMLA in detecting mediastinal metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative predictive value (NPV) of TEMLA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful biliary cannulation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Equilibrium scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscular response latencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sway areas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: airway secretions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in AHI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Efficacy of interferon-beta preparations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin tolerance of intramuscularly administered interferon-beta
Endpoint domain: Adverse events/effects
Primary endpoint: Systemic adverse event profile for glatiramer acetate
Endpoint domain: Adverse events/effects
Primary endpoint: Compliance with record-keeping
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Altered respiratory function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of combined outcome measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Cost-effectiveness ratio per quit attempt
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cost per additional quit attempt
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cost per additional quit
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: survival and success rates
Endpoint domain: Mortality/survival
Primary endpoint: Age verification for alcohol purchases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time-to-Progression (TTP)
Endpoint domain: Mortality/survival
Primary endpoint: abstinent days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: liver enzyme γ‐glutamyl transpeptidase concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean haemoglobin difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Panic attack status after CO2 challenge test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Panic free status after clonazepam treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coronary sinus concentrations of F1.2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: mean bone union time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FACES score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Norfolk QOL-DN total score change
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: UENS total score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Five-year failure-free survival (FFS)
Endpoint domain: Mortality/survival
Primary endpoint: anterior chamber depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of EIT in diagnosis of breast lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Sensitivity of EIT in diagnosis of breast lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Specificity of EIT in diagnosis of breast lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Satisfaction with communication
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Loss of Appendicular Lean Mass (ALM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Loss of Skeletal Muscle Index (SMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: overall comprehension
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: exercise test time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: attendance rate
Endpoint domain: Resource use
Primary endpoint: Level of sensory block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Plasma cytokine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HPV knowledge assessment scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HPV vaccine acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Satisfaction rates by nephrologists and patients
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: clinical and radiographic success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in logical memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: improvement in visual memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: improvement in psychomotor speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: PLD AUC(inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PLD clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to LMA removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: 5-km time-trial performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Tregs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: complete STR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MBG‐3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak creatine kinase-mass band fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Angiographic success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Six-month binary restenosis rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes